Sativex occupies an unusual place in the history of medical cannabis. Rather than being dried marijuana, a dispensary tincture, or a purified single cannabinoid, it is a standardized prescription medicine manufactured from extracts of Cannabis sativa. Also known by the generic name nabiximols, Sativex delivers controlled amounts of both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) through an oromucosal spray. Its development provided researchers and regulators with something that conventional cannabis often cannot: a reproducible product with a known cannabinoid composition, standardized dosing, pharmaceutical manufacturing controls, and randomized clinical-trial evidence.
Sativex is best established as an add-on treatment for moderate to severe muscle spasticity caused by multiple sclerosis when conventional anti-spasticity medications have not provided adequate relief. It has been authorized in the United Kingdom and numerous other countries, although as of 2026 it remains unavailable as an FDA-approved medicine in the United States. Research has also explored nabiximols for neuropathic pain, cancer pain, and other neurological symptoms, with results ranging from encouraging to inconclusive. Understanding the medicine therefore requires separating its well-supported role in multiple sclerosis from broader claims sometimes made about cannabis-based treatments.
What Is Sativex?
Sativex is a botanical cannabis extract formulated as a metered oromucosal spray. According to its current United Kingdom prescribing information, each 100-microliter spray provides approximately 2.7 milligrams of THC and 2.5 milligrams of CBD. The cannabinoids are extracted from cannabis leaves and flowers using carbon dioxide and formulated with ethanol, propylene glycol, and peppermint oil. Unlike smoked or vaporized marijuana, the medicine is sprayed onto the inside of the cheek or under the tongue, allowing cannabinoids to be absorbed through the oral mucosa as well as through the gastrointestinal tract after swallowing.
The nearly one-to-one THC-to-CBD ratio is one of the product’s defining characteristics. THC activates cannabinoid receptors and is responsible for much of cannabis’s psychoactive and muscle-relaxing activity, while CBD has substantially different pharmacological actions and does not produce the typical THC high by itself. Sativex nevertheless contains enough THC to produce dizziness, sleepiness, altered concentration, and other cannabinoid effects. Calling it a CBD medicine would therefore be inaccurate; it is a standardized THC-and-CBD pharmaceutical preparation.
How Sativex Works
THC primarily acts as a partial agonist at cannabinoid CB1 and CB2 receptors. CB1 receptors are abundant throughout the central nervous system, including areas involved in movement, sensory processing, pain, memory, and muscle control. In multiple sclerosis, abnormal muscle tone and involuntary spasms arise because damage within the brain and spinal cord disrupts pathways controlling muscular contraction. Modifying cannabinoid signaling appears capable of reducing the subjective severity of spasticity in some patients even when conventional anti-spasticity treatments have failed.
CBD interacts with the endocannabinoid system much less directly and influences a much wider range of molecular targets. Its precise contribution to the clinical effects of nabiximols is still being investigated. The combination does not simply neutralize THC; patients can still experience psychoactive or neurological effects. However, administering THC alongside CBD in small, gradually titrated doses creates a considerably different pharmacological experience from rapidly inhaling high-potency recreational cannabis.
This standardized formulation has also allowed researchers to study cannabinoid medicine in ways that are difficult with ordinary marijuana. Different cannabis flowers can contain dramatically different amounts of THC, CBD, minor cannabinoids, and terpenes. By comparison, each Sativex spray provides essentially the same cannabinoid dose, making the relationship between treatment, side effects, and clinical response easier to evaluate.
Sativex and Multiple Sclerosis Spasticity
Multiple sclerosis is an inflammatory neurological disease in which the immune system damages myelin and other structures within the central nervous system. Spasticity is among its most troublesome symptoms and can cause persistent muscle stiffness, painful spasms, impaired walking, sleep disturbance, and difficulty performing everyday tasks. Traditional medications such as baclofen and tizanidine can help, but some patients either respond inadequately or cannot tolerate their adverse effects.
The United Kingdom’s National Institute for Health and Care Excellence recommends a four-week trial of THC spray for adults with moderate to severe MS spasticity when other pharmacological treatments have not been effective. Treatment is continued only when the person achieves at least a 20 percent improvement on a patient-reported 0-to-10 spasticity scale. NICE specifically recommends specialist supervision, reflecting the idea that Sativex is not intended as a routine first-line cannabis treatment but as an add-on option for selected patients with persistent symptoms.
That responder approach has become central to how the medicine is used. Instead of assuming that every patient with MS will benefit, clinicians identify those showing a meaningful response during an initial treatment period. Those who do not improve are expected to stop the medicine, reducing unnecessary long-term cannabinoid exposure and cost.
What Clinical Trials Have Found
The evidence for MS-related spasticity has accumulated through randomized controlled trials, observational studies, registries, and meta-analyses. An earlier Oxford-led meta-analysis combined three randomized placebo-controlled trials involving 666 patients. Patients receiving nabiximols experienced greater improvement in self-reported spasticity than those receiving placebo, and a larger proportion reached clinically meaningful response thresholds. A subsequent randomized withdrawal trial strengthened the evidence by first identifying patients who responded to Sativex and then randomly assigning responders either to remain on treatment or switch to placebo. Symptoms worsened more among those switched away from active treatment.
A 2023 systematic review and meta-analysis examined seven randomized trials containing 1,128 participants and concluded that add-on nabiximols significantly increased the likelihood of improvement among patients with MS spasticity that had remained resistant to standard treatment. Researchers calculated an odds ratio of approximately 2.4 for spasticity response with nabiximols compared with placebo, although they also noted concerns about bias and called for additional research into optimal treatment duration and dosing.
More recently, a 2026 systematic review and meta-analysis evaluated 20 studies examining Sativex for pain, spasticity, and disability in multiple sclerosis. Researchers reported significant reductions in both pain intensity and spasticity severity, along with a smaller improvement in disability scores. The authors concluded that Sativex can be an effective option for managing MS-related spasticity and pain, while the relatively modest disability effect illustrates an important limitation: reducing symptoms is not equivalent to reversing the neurological disease itself.
Sativex for Pain
Cannabinoid signaling is closely involved in pain processing, so Sativex has naturally been investigated for neuropathic and chronic pain. Some randomized trials in people with multiple sclerosis have reported reductions in neuropathic pain, sleep disturbance, and related symptoms. The U.S. National Center for Complementary and Integrative Health notes that mucosally administered THC/CBD extracts such as nabiximols have been studied for both spasticity and pain in MS, with evidence suggesting that cannabinoids may offer symptomatic benefit.
Results become much less consistent outside MS. In chemotherapy-induced peripheral neuropathy, a small randomized crossover study of 16 patients failed to find a statistically significant benefit for the group as a whole, although several participants appeared to respond substantially. Cancer-pain trials have also produced mixed results. One 360-patient trial found no statistically significant advantage on its primary responder endpoint, although lower and moderate doses performed better than placebo on several secondary pain analyses. Later Phase III studies failed to demonstrate clear superiority over placebo on their primary pain endpoints.
A Cochrane review examining cannabis-based medicines for cancer pain reached an appropriately cautious conclusion. Across trials containing more than 1,500 participants with inadequately controlled cancer pain, nabiximols or THC did not produce a clinically meaningful average reduction in pain intensity compared with placebo. These findings are important because they demonstrate that success in MS spasticity does not mean Sativex should automatically be considered effective for every painful condition.
How Sativex Is Dosed
Sativex is not given as a fixed number of sprays to every patient. Treatment begins at a low dose and is gradually increased so that the patient can find a balance between symptom control and adverse effects. Current prescribing information advises increasing the dose progressively during the titration period rather than delivering multiple sprays at once. At least 15 minutes should separate individual sprays during titration.
The optimal daily dose varies considerably. The median dose in MS clinical trials has been approximately eight sprays per day, corresponding to about 21.6 milligrams of THC and 20 milligrams of CBD. Doses above 12 sprays per day are not recommended under current UK prescribing guidance. Once an effective dose has been established, sprays can be distributed throughout the day according to symptoms and tolerability. If medications, disease severity, or adverse effects change, the dose may need to be adjusted.
The four-week evaluation remains important even after successful titration. Patients who fail to achieve a meaningful reduction in spasticity during that period are unlikely to benefit enough to justify continuing therapy. Those who respond may remain on treatment, but the usefulness of long-term therapy should still be reassessed periodically.
Side Effects and Safety
The most consistently reported Sativex side effects involve the nervous system. Dizziness and fatigue are particularly common, especially during the early titration period. Other reported effects include sleepiness, nausea, dry mouth, impaired concentration, confusion, vertigo, and a sensation of intoxication. A long-term study involving 146 patients with MS found that dizziness occurred in approximately one-quarter of participants and fatigue in about 12 percent. Most adverse events were mild or moderate, although some patients discontinued treatment because of side effects.
Real-world results generally resemble the clinical-trial experience. A Swiss multicenter study reported that only a small proportion discontinued nabiximols because of adverse effects during 12 weeks of treatment; dizziness was again the most frequently reported problem. Meanwhile, a large Italian registry involving more than 1,600 patients demonstrated that Sativex could be implemented in routine MS clinics using the initial responder approach rather than simply prescribing the medication indefinitely to everyone.
Driving is an especially important safety consideration because THC can impair reaction time and judgment. Current patient guidance warns people not to drive or operate machinery when first beginning Sativex or while the dose is changing. Even after reaching a stable dose, driving should be avoided whenever dizziness, drowsiness, or other impairing effects occur. Alcohol can intensify some of these effects.
Sativex Is Not the Same as Marijuana
Although Sativex originates from cannabis, equating a prescription of nabiximols with smoking marijuana overlooks fundamental differences. Pharmaceutical manufacturing provides a known dose with each spray, controlled ratios of THC and CBD, standardized production, formal stability testing, and regulatory oversight. Marijuana flower purchased from a dispensary may vary substantially among cultivars and even batches of the same cultivar. Concentrated vape cartridges and extracts can expose users to much larger THC doses over a much shorter period than nabiximols.
Route of administration also changes the experience. Inhaling cannabis produces a rapid rise in THC concentration, often within minutes. Oromucosal Sativex is absorbed more gradually, and its small sprays allow patients to titrate their exposure incrementally. That does not eliminate psychoactive effects, but it makes medical dosing more controlled. These distinctions help explain why regulatory organizations may approve a specific cannabinoid medicine without concluding that cannabis in every form has proven efficacy for the same indication.
The distinction is especially important in the United States. Sativex remains not FDA-approved as of 2026, despite clinical development and prior FDA Fast Track designation for research involving advanced cancer pain. A recent JAMA review and the U.S. Agency for Healthcare Research and Quality’s continuing review of cannabis-based chronic-pain treatments both identify nabiximols as available in countries such as the United Kingdom and Canada but not as an FDA-approved medication in the United States.
Sativex and the Evolution of Medical Cannabis
Sativex is historically significant because it challenged the idea that cannabis medicines must fall into one of two categories: traditional marijuana or isolated synthetic cannabinoids. Nabiximols instead demonstrated that a whole-plant-derived cannabis extract could be standardized sufficiently to undergo conventional pharmaceutical development. The UK Medicines and Healthcare products Regulatory Agency granted the product marketing authorization for MS-related spasticity in 2010, making it the first cannabis-based medicine formally recognized in that country for medicinal use.
Its history also illustrates why regulatory approval is indication-specific. Evidence sufficient to support treatment-resistant MS spasticity did not automatically translate into approval for cancer pain, general chronic pain, or other conditions. NICE specifically recommends THC spray for selected adults with MS spasticity while advising against routinely offering THC, CBD/THC combinations, or CBD alone for general chronic pain outside the circumstances defined in its guidance.
That separation is scientifically important. Cannabinoids clearly possess biological activity, but whether that activity produces worthwhile clinical benefits depends on the condition, dose, formulation, patient population, and outcome being measured.
Final Thoughts on Sativex
Sativex is one of the most extensively studied prescription cannabis medicines in the world. Each spray delivers a standardized dose of approximately 2.7 milligrams of THC and 2.5 milligrams of CBD, and its clearest therapeutic role is as an add-on treatment for adults with moderate to severe multiple-sclerosis spasticity that has not responded adequately to conventional medication. Randomized controlled trials, registry studies, and several meta-analyses support meaningful symptom improvement in a proportion of these patients, leading regulators such as NICE to recommend a time-limited trial followed by continued treatment only in responders.
The wider evidence is more complicated. Nabiximols may help certain forms of neuropathic pain, and recent research continues to show reductions in MS-associated pain, but large cancer-pain studies have generally failed to demonstrate a convincing average benefit over placebo. Side effects—particularly dizziness, fatigue, drowsiness, and cognitive impairment—also become increasingly important as the dose rises. Sativex therefore represents neither proof that cannabis treats every medical condition nor evidence that cannabinoid medicine lacks value. Instead, its development demonstrates what happens when cannabis-derived compounds are treated like other medicines: standardized precisely, tested for particular diseases, prescribed at controlled doses, and continued only when the measurable benefit justifies the risks.
